Group items matching

in title, tags, annotations or url

The National Institute on Aging is seeking applications to develop systems biology approaches to understand the basic biology underpinning neurodegeneration which might ultimately contribute to Alzheimer's disease or related dementias, using non-mammalian laboratory animal models. It is expected that research carried under the auspices of this FOA will lead to discovery of new mechanisms that provoke neurodegeneration and to new molecular pathways that might be involved in causing, amplifying or protecting against neurodegeneration. Applications should propose to use established non-mammalian laboratory animals which have a history of contributions to our understanding of neurobiology or aging biology.  

This FOA invites applications on descriptive, basic and translational studies of APOE2 to delineate the functional effects of ApoE2 on healthy aging of the brain and other tissues. The primary focus is on the "APOE2-Aging-AD" relationship and the mechanistic effects of the protective variant on aging and potential interaction/cross talk between tissues in the aging process and AD. These studies are expected to generate new mechanistic insights that involve brain and/or other organs and assist in the identification of potential prognostic and diagnostic markers and therapeutic targets for AD and other age-related cognitive disorders. Eventually, the findings from these studies could lead to translational research opportunities not only to prevent or delay the onset of AD, but also to protect against multiple age-related conditions.  

This FOA is soliciting research projects that would advance biomedical research on the role of peripheral proteostasis on brain structure and function during aging and in Alzheimer's disease, facilitating the identification of molecular and cellular markers of normal brain aging and brain aging during pathological conditions.

The goal of this FOA is to define and characterize neural cell populations, neural circuits, and brain networks and regions that are vulnerable to brain aging and Alzheimer's disease (AD). Understanding mechanisms underlying selective vulnerability from cells to networks in AD is critical to fully define the disease process and to develop effective therapies. 

This funding opportunity announcement invites comprehensive, cross-disciplinary studies aimed at building predictive molecular models of cognitive resilience based on high-dimensional molecular data collected in individuals who remain free of dementia despite being at high risk for Alzheimer's disease. 

This FOA invites applications that will combine multiple cohorts in order to improve statistical power and clarify risk and protective factors for Alzheimer's disease and related dementias (AD/ADRD).

This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimer's disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

This FOA invites Research and Development Center (P30) grant applications in demography, economics and health services research relevant to Alzheimer's Disease and Alzheimer's Related Dementias (AD/ADRD). Areas of focus that are especially encouraged are: a) national and international population trends in cognitive aging and AD/ADRD; b) demography of dementia care and caregiving; c) economic burden of AD/ADRD; d) impact of health care systems and long-term supports and services on outcomes for persons with dementia and their care providers; e) impact of health care financing policies on outcomes for persons with dementia and their care providers; f) how regulatory and economic incentives affect access, quality and health outcomes in health and long-term care systems for persons with dementia; g) disparities in quality and access to dementia care; h) effects of population-level health delivery and care interventions on outcomes of persons with dementia; and i) national and international projections of dementia caseload, incidence and prevalence. Center grant applications must include two mandatory Cores and may choose among three optional Cores. Centers are required to work collaboratively with the Coordinating Center to be funded via RFA-AG-20-003.  

he goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide insights into novel targets for interventions that might alleviate some burden associated with these symptoms, or suggest strategies for preventing the development of NPS as related to AD or ADRD 

This Funding Opportunity Announcement (FOA) invites applications that propose to develop and implement early stage (Phase I or II) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and in individuals with Alzheimer's disease (AD) across the spectrum from pre-symptomatic to more severe stages of disease, as well as to stimulate studies to enhance trial design and methods.

The goal of this Funding Opportunity Announcement (FOA) is to encourage biomedical, behavioral and social sciences research that will enhance knowledge of mechanisms underlying neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD) so as to enable novel treatment development. NPS, or Behavioral and Psychological Symptoms of Dementia (BPSD), include aggression, psychosis, anxiety, apathy, depression, agitation, sleep disturbances and wandering, and can be significant challenges to the care and treatment of people with dementia. These symptoms lead to accelerated declines in both functional abilities and may lead to earlier nursing home placement. Currently, few pharmacological treatments are available. In addition, there is a need to understand behavioral and environmental targets to further refine and develop promising behavioral treatments for these disorders.  

Grants of up to $300,000 over two years will be awarded in support of projects focused on the development of biomarkers previously identified in samples from well-characterized human subjects. Validated methods should be used in quantifying and qualifying biomarkers, with less enthusiasm for the development of novel technologies. Priority biomarker areas include companion biomarkers, neuroimaging, CSF and blood-based biomarkers, and functional activity measures.

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide clues to novel intervention targets for alleviating some of the burden associated with these symptoms, or suggest optimal prevention strategies.

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD).The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide insights into novel targets for interventions that might alleviatesomeburden associated with these symptoms, or suggest strategies for preventing the development of NPS as related to AD or ADRD RFA-MH-19-510 uses the R01 grant mechanism, whileRFA-MH-19-511 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.

This FOA invites applications that propose to develop, characterize and validate innovative human cellular model systems that recapitulate phenotypic, mechanistic and neuropathological hallmarks of  Alzheimer's Disease-Related Dementias (ADRDs). Model systems will be expected to capture the complex, multi-faceted proteinopathies and/or vascular pathology observed in ADRDs, with multiple cell types represented in each model. Years 3-5 will focus on the extensive characterization and perturbation of the cellular model systems. The overall goal of this FOA is to establish next generation human cellular model systems for ADRDs to serve as tools to interrogate molecular disease mechanisms and identify potential therapeutic targets.

To that end, grants of up to $5 million will be awarded in support of research on innovative pharmacologic interventions for Alzheimer's disease and related dementias, including clinical trials, regulatory studies for novel drugs (small molecules and biologics, including antibodies, peptides, gene therapies), repurposed drugs (existing drugs that are approved for other diseases and conditions), repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved), and natural products.

As part of a network, Centers are expected to participate in collaborative efforts on a national scale. Applicants must agree to collect a standard clinical data set (the Uniform Data Set, or UDS) that is common to all Centers and to transmit that data to the National Alzheimer's Coordinating Center (NACC). Applicants should contact NACC to learn more about NACC procedures, the structure of the UDS, and the regular updates to the datasets required from all Centers at  http://www.alz.washington.edu/.  To support the unique research needs of the NACC, most Centers collect additional data to supplement those required by the UDS. These should also be made readily available to qualified investigators. Similarly, Centers should demonstrate a readiness to provide biological samples and data, with proper consent from well-characterized populations, to enable participation in large-scale, collaborative, national, or international research projects. Sample sharing may be done either locally or centrally through the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD). Centers are a local, regional, national, and international resource.

This Funding Opportunity Announcement (FOA) invites applications that seek to enhance existing transcriptome and proteome data sets by revealing oscillatory patterns of gene expression in aging and in Alzheimer's disease (AD), by uncovering their molecular significance, and by identifying rhythmic gene and/or protein profiles associated with the risk for AD. Outcomes of this research may suggest novel opportunities for translational research to allow development of individualized, optimized treatment based on circadian phase and amplitude.

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

To study in vivo synaptic structure and function in Alzheimer's and related dementia; and to advance development of methods to study synapses in animal models and humans.